JonesTrading analyst Justin Walsh reiterated a Buy rating on Lantheus today and set a price target of $70.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Walsh has given his Buy rating due to a combination of factors that highlight Lantheus’s potential for growth and stability. The company’s recent earnings report showed that PYLARIFY revenue exceeded expectations, indicating a strong market position despite a year-over-year decline. Management’s confidence in stabilizing pricing and competing effectively suggests a positive outlook for future sales, particularly with the anticipated momentum in late 2026.
Furthermore, Lantheus’s strategic acquisitions from Life Molecular Imaging and Evergreen Theragnostics are expected to drive medium- to long-term growth, independent of current challenges. The company’s robust cash position and access to a significant line of credit provide financial flexibility to support pipeline expansion and capitalize on growth opportunities. These factors, combined with a risk-adjusted discounted cash flow valuation, underpin the $70 price target and reinforce the Buy recommendation.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $70.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LNTH in relation to earlier this year.